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| INTRODUC TI ON
As a leading cause of death worldwide, cancer is a big problem for human beings. 1 It was reported that there were 14.1 million newly diagnosed cases and 8.2 million deaths resulted from poor prognosis and post-operative care each year despite of advancement of cancer diagnosis and treatment. [1] [2] [3] Therefore, novel biomarkers for predicting cancer prognosis were important and urgently needed for therapeutic decision-making and improving the care after surgery. 4 Long non-coding RNAs (lncRNAs), longer than 200 nucleotides in length, are mRNA-like transcripts and cannot be translated into proteins. 5, 6 It is being increasingly recognized that abnormal expression of lncRNAs is specifically related to tumorigenesis, tumour progression and metastasis. 7, 8 As a kind of potential and novel cancer biomarker, Despite some studies that reported the association between lncRNA GHET1 and cancers, there has been still no consistent conclusion on the prognostic value of lncRNA GHET1 in cancer patients because of different outcomes and limited sample size in each individual study. [17] [18] [19] [20] [21] [22] Therefore, we conducted this meta-analysis to identify the relationship between the expressions of lncRNA GHET1
in a variety of human cancers and the patients' overall survival (OS)
as well as other clinical parameters, identifying the prognostic value of lncRNA GHET1 as a novel biomarker for human cancers.
| MATERIAL S AND ME THODS
Our systematic review and meta-analysis was reported according to the recommendations of the PRISMA statement. 23 
| Literature retrieval strategy
In order to collect all articles eligible for this study, we retrieved key- Other additional studies were obtained by screening the reference list.
The articles only written in English were included in this meta-analysis.
| Inclusion and exclusion criteria
Eligible articles enrolled in this meta-analysis meet the following criteria:
(a) patients included were diagnosed with cancers; (b) the expression of or (c) letters, reviews, case reports and expert opinions.
| Data extraction and quality assessment
Two authors extracted the information and data from included studies independently, and any disagreement was resolved by consulting with the third author. The information and data were as following: For the HRs and 95% CIs of survival, the data were recorded directly from articles provided the detail information. Two individual authors extracted the data from those provided Kaplan-Meier curves only with the Engauge Digitizer version 4.1. To evaluate the quality of included studies, the Newcastle-Ottawa Scale (NOS) was applied, whose score is ranging from 0 to 9 points. 24, 25 Studies' NOS score, 7-9, has been regarded as high quality. and the chi-squared test (P ≤ 0.10). If the statistical heterogeneity was significant, random-effects model was then preformed. [26] [27] [28] [29] In addition, we preformed Begg's rank correlation test to assess the publication bias for the HRs for OS, determined as positive by Pr>|z|≤0.1. We also did a sensitivity analysis to check the stability of results for OS.
| Statistical methods
Moreover, subgroup analyses of OS were performed.
| RE SULTS

| Literature search
A total of 12 eligible articles containing 761 patients with cancers were included in this meta-analysis after screening titles, abstracts or full texts. 18, 21, 22, [30] [31] [32] [33] [34] [35] [36] [37] [38] The process of article selection was shown in Figure 1 .
| Main information of included studies
In these studies, the sample size ranged from 42 to 105, among a total of 761 participants. The main characteristics of included studies were presented in Table 1 . Among the 12 studies, there were various types of cancers, including non-small cell lung cancer (two articles), hepatocellular carcinoma, bladder cancer, oesophageal squamous cell carcinoma, head and neck cancer, breast cancer (two articles), gastric cancer (three articles) and pancreatic cancer. Among these studies, one came from Iran, all others came from China. The publication period of these articles ranged from 2014 to 2018. The samples of all these studies were from cancer and matched normal tissues. In addition, the level of lncRNA GHET1 was detected by quantitative reverse transcription polymerase chain reaction (qRT-PCR). There were four different cut-off points for the 12 studies: four median level, four median ratio, one average level and three not reported. In regard to disease outcomes, eight studies reported OS, one study reported DFS, the remnant reported clinical parameters. The high-quality studies in this meta-analysis have NOS score: 7-9.
| Association between lncRNA GHET1 expression and OS
Seven articles investigated the association between lncRNA GHET1 expression and OS with a total of 553 cancer patients. 21, 22, 30, 32, [34] [35] [36] 38 We used fix-effect model to analysis the HR of OS because of no 
| Association between lncRNA GHET1 expression and clinical parameters
According to meta-analysis results of Table 3 
| Publication bias
No obvious bias was detected by the funnel plot ( Figure 6 ) and Begg's test in HRs for OS (P = 1.000). We did not proceed Begg's test for other clinical parameters, because of no enough studies included (n < 10).
| Sensitivity analysis
Sensitivity analysis was performed by removing one study every time from the pooled analysis to check the stability of results for OS of each study ( Figure 7 ).
| D ISCUSS I ON
As lncRNAs play important roles in the process of genes' transcription and translation, their dysregulation has been increasingly identified as a hallmark feature in the progression of cancer. GHET1, a novel identified lncRNA, was significantly over-expressed in the gastric cancer. 36 It has been confirmed to be an oncogene through some biological process in a variety of cancers although the role of GHET1 in cancers remains unclear yet. 17, 21, 31, 35 In addition, the prognosis value of GHET1 expression in cancer and association between high expression of GHET1 and tumour stage, differentiation, has also been widely reported. 21, 22, 30 In our meta-analysis, we found that lncRNA GHET1 might be an unfavourable prognosis factor for cancer patients. Higher expression of A few highlights exist in our study. Firstly, this is the first study comprehensively explored the relationship between the GHET1 expression level and prognostic outcomes in human cancers based on our knowledge. Secondly, the methodology and results are credible as we followed recommendations of the PRISMA statement. 23 Furthermore, the results are relatively accurate because of a fixedeffect model used in most of our analysis.
However, there are some limitations in our meta-analysis. First, the number of patients included was relatively small, which might lead to inadequate stringency. Second, all studies included were retrospective studies. Most of them were from China, which may be more preferential in China. Third, the cut-off values for positive GHET1 expression were not always consistent in different studies.
However, all of them can reflect the tendency of GHET1 expression and no statistical heterogeneity was found among them, including publication bias analysis and sensitivity analysis. Fourth, the HRs 
